Evidence map›Paper›PMID 32486846›Full record

ArticleJournal of diabetes science and technology2020

Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic: Is the Benefit to Risk Ratio Still Favorable?

Theocharis Koufakis, Symeon Metallidis, Pantelis Zebekakis, Ramzi A Ajjan, Kalliopi Kotsa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes science and technology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Hospital Diabetes Meeting 2022.Journal of diabetes science and technology · 2022
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. COVID-19 in Relation to Hyperglycemia and Diabetes Mellitus.Frontiers in cardiovascular medicine · 2021
    Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Theocharis KoufakisDivision of Endocrinology and Metabolism and Diabetes Centre, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Greece.ORCID https://orcid.org/0000-0002-5853-1352
Symeon MetallidisInfectious Diseases Division, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Greece.
Pantelis ZebekakisDivision of Endocrinology and Metabolism and Diabetes Centre, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Greece.
Ramzi A AjjanLeeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, UK.
Kalliopi KotsaDivision of Endocrinology and Metabolism and Diabetes Centre, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BetacoronavirusCardiovascular DiseasesCoronavirus InfectionsCOVID-19CytokinesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetic KetoacidosisHumansMetforminOxidative StressPandemicsPneumonia, ViralPrognosisRisk AssessmentRisk FactorsCytokinesMetforminSodium-Glucose Transporter 2 InhibitorsCOVID-19diabetesdiabetic ketoacidosisSGLT2 inhibitors

Identifiers

PMID32486846
PMCPMC7673172

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.